Investment Highlights
Nexalis Therapeutics is a clinical-stage biopharmaceutical company with a diversified pipeline addressing significant unmet medical needs.
Pain & mental health therapies
HREC approved, ready to dose
Linlithgow Family Office
Esketamine + CYP-450 inhibitor
IRX-211 & IRX-616a batches
Innovation patent approved
Share price data is currently unavailable.
Share Information
Nexalis Therapeutics is listed on the Australian Securities Exchange.
- ASX Code
- NX1
- Sector
- Healthcare / Pharmaceuticals
- Registry
- Automic Group
Funding Position
Nexalis has secured a total funding facility of $52.3 million with Linlithgow Family Office to support clinical development across all three pipeline programs.
Share Price Chart
Chart data is currently unavailable.
Investor Documents
Presentations
- Nexalis Therapeutics Investor Deck 2025 1 Jan 2025
ASX Announcements
All market-sensitive announcements lodged with the ASX, updated live.
View all announcements →Reports
Annual and quarterly reports coming soon
Corporate Governance
Nexalis Therapeutics is committed to maintaining high standards of corporate governance. Our governance framework ensures accountability, transparency, and ethical conduct. View governance documents →
Board & Management
- Sean Williams Non-Executive Chairman
- Dr Ron Wise Non-Executive Director
- Tony Fitzgerald Non-Executive Director
- Darryl Davies Chief Executive Officer
- James Barrie Company Secretary
Corporate Directory
Key corporate and registry information for shareholders and investors.
- Registered Office
- Level 9, 505 Little Collins Street
Melbourne VIC 3000, Australia - ASX Listing
- ASX: NX1
- ACN
- 611 845 820
- Investor Contact
- info@nexalistherapeutics.com
- ASX Announcements
- View on ASX →